Aon Agrees to $17 Billion Deal for Rival Broker USI
The deal adds debt, pauses buybacks, and hits EPS in 2028.
Already have an account? Sign in.
The deal adds debt, pauses buybacks, and hits EPS in 2028.
Tempest gets an exclusive option to license Senlang’s CD7-targeted lentiviral in-vivo CAR-T, now in Phase 1 for relapsed multiple myeloma.
Axon plans $1 billion of 0% convertible notes due 2031, plus a $150 million option.
Senators failed to reach 60 votes on the Clarity Act. All Democrats and four Republicans stopped debate on digital asset rules.